Neurohypophyseal Peptides from Prague and Swedish Laboratories. Part 1: History of Re-search and Beginnings of Industrial Production
Authors:
V. Pliska 1; A. Pařízek 2; M. Flegel† 3*
Authors‘ workplace:
Department of Biology, Eidgenössische Technische Hochschule (ETH), Wofgang-Pauli-Strasse 27, CH-8093 Zürich
1; Gynekologicko-porodnická klinika 1. lékařské fakulty UK a VFN v Praze, Perinatologické centrum, Apolinářská 18, 128 51 Praha 2
2; Ústav chemie přírodních látek, Vysoká škola chemicko-technologická v Praze, Technická 5, 166 28 Praha 6
3
Published in:
Ceska Gynekol 2023; 88(2): 140-147
Category:
Review
doi:
https://doi.org/10.54779/ chl20220020
Overview
From the fifties to the seventies of the last century, the neurohypophyseal peptides oxytocin and vasopressin constituted one of the main research areas at the Institute of Organic Chemistry and Biochemistry in Prague (IOCB). A significant contribution to this area is associated with the names of František Šorm, director of the said institute, and Josef Rudinger, head of the institute’s peptide laboratory. At that time, newly developed research tools enabled to synthesize structural analogues of these hormones in numerous laboratories worldwide and hence to investigate the structure-activity relationships within this peptide group. Contributions of single peptide-chain positions to the respective biological activities were identified which opened a possibility to rationalize a design of peptides with a combination of changes in several positions. Several clinically interesting peptides were synthesized in the late 1960s at the IOCB and employed as therapeutics: [ (Gly) 3-Cys1,Lys8]-vasopressin (Glypressin Ferring®, Terlipressin INN), 1-deamino-8-D-arginine vasopressin (Desmopressin INN, dDAVP), and later the uterotonics carbetocin (INN), widely used in obstetrics to prevent postpartum haemorrhage. Since the industrial production of peptide therapeutics was scarcely possible under the conditions of socialist economy in Czechoslovakia as well as in other countries under the Soviet influence, F. Šorm agreed to use the already established scientific contacts of IOCB with the Swedish pharmaceutical company Ferring AB and to transfer the production licences to Sweden. The license agreements were signed in 1969 and led to a quick spread of dDAVP in the substitution therapy of the central form of diabetes insipidus and, moreover, contributed to a fast upsurge of the Ferring company. Somewhat later, Glypressin was produced as a therapeutic with a prolonged action in cases of cardiovascular collapse. Contacts between Prague peptide chemists and the Ferring company lasted on a rather informal base until the end of the 1980s. After the fall of the totalitarian regime in Czechoslovakia in 1990, Ferring started a joint-venture collaboration with the newly organized Czech company Léčiva st.p. Praha in a newly established group Prague Poly-peptide Institute spol. s. r. o. (later Ferring-Léčiva a. s.). A substantial part of the peptide-production capacities was then transferred to new buildings in Prague.
Keywords:
Oxytocin – Vasopressin – terlipressin – carbetocin – dDAVP – deamino-D-arginine vasopressin – atosiban – neurohypophyseal hormones – Glypressin – Ferring company – peptide drugs
Sources
1. Pliska V., Pařízek A., Flegel M.: Chem. Listy 113, 675 (2019).
2. Dale H. H.: Biochem. J. 4, 427 (1909).
3. Blair Bell W.: Br. Med. J. 2, 1609 (1909).
4. Foges A.: Archiv für Gyneakologie 99, 455 (1913).
5. Blair Bell W.: Proc. R. J. Med. 8, 71 (1915).
6. Lindholm J.: Pituitary 7, 33 (2004).
7. Farini F.: Gazz. Osp. Clin. 34, 1135 (1913).
8. von den Velden R.: Berl. Klin. Wochenschr. 50, 2083 (1913).
9. Saameli K., v knize: Neurohypophysial Hormones and Similar Polypeptides (Berde B., ed.), str. 577. Springer-Verlag, Berlin, Heidelberg 1968.
10. du Vigneaud V., Ressler C., Swann J. M., Roberts C. W., Gordon S., Katsoyannis P. G.: J. Am. Chem. Soc. 76, 3115 (1954).
11. du Vigneaud V., Ressler C., Swann J. M., Roberts C. W., Katsoyannis P. G., Gordon S.: J. Am. Chem. Soc. 75, 4879 (1953).
12. du Vigneaud V., Gish D. T., Katsoyannis P. G.: J. Am. Chem. Soc. 76, 4751 (1954).
13. Boissonnas R. A., Guttmann S., Jaquenoud P.-A., J.-P. Waller J.-P.: Helv. Chim. Acta 28, 1491 (1955).
14. Rudinger J., Honzl J., Zaoral M.: Collect. Czech. Chem. Commun. 21, 202 (1956).
15. Boissonnas R. A., Guttmann S., v knize: Neurohypo-physial Hormones and Similar Polypeptides (Berde B., ed.), str. 40. Springer Verlag, Berlin 1968.
16. Krejčí I., Poláček I.: Eur. J. Pharmacol. 2, 393 (1968).
17. Krejčí I., Poláček I., Rudinger J.: Br. J. Pharmacol. Chemother. 30, 506 (1967).
18. Navrátil K.: Československá Farmacie 15, 540 (1966).
19. Hodr J., Štembera Z. K., Brotánek V., Rudinger J., Vondráček J., v knize: Intra-Uterine Dangers to the Foetus: Based on an International Symposium, Pra-gue, October 11th-14th, 1966 (Horský J., Štembera Z. K., Merkatz I. R., Dennis K. J., ed.), 12. díl, str. 445. Excerpta Medica Foundation, Amsterdam 1967.
20. Kynčl J., Řežábek K., Kasafírek E., Pliška V., Rudinger J.: Eur. J. Pharmacol. 28, 294 (1974).
21. Rudinger J., Pliška V., Krejčí I.: Rec. Prog. Horm. Res. 28, 131 (1972).
22. Zaoral M., Kolc J., Šorm F.: Collect. Czech. Chem. Commun. 32, 1250 (1967).
23. Vávra I., Machová A., Holeček V., Cort J. H., Zaoral M., Šorm F.: Lancet 291, 948 (1968).
24. Vávra I., Machová A., Krejčí I.: J. Pharmacol. Exp. Ther. 188, 241 (1974).
25. Rudinger J., Pliška V., Rychlík I., Šorm F., v knize: Pharmacology of Hormonal Polypeptides and Proteins (Back N., Martini L., Paoletti R., ed.), str. 66. Plenum Press, New York 1968.
26. Pliška V., Barth T., Thorn N. A.: Acta Endocrinol. 67, 1 (1971).
27. Pliška V., Thorn N. A., Vilhardt H.: Acta Endocrinol. 67, 12 (1971).
28. Carlsson L., Sjöholm I.: Acta Chem. Scand. 20, 259 (1966).
29. Sjöholm I., Carlsson L.: J. Labelled Compd. 3, 3 (1967).
30. Pliška V., Meyer-Grass M., Bersinger N., Carlsson L., Melin P., Vilhardt H.: Experientia 36, 1145 (1980).
31. Amon B.: Ahead of His Time. Ferring Gmbh, Kiel, BRD 1999.
32. Jost K., Pliska V., Krejcí I., Sorm F.: U.S. Patent 3,973/69 (1973).
33. Jošt K., Šorm F.: Collect. Czech. Chem. Commun. 36, 297 (1971).
34. Melin P.: Regul. Pept.45, 285 (1993).
35. Melin P., Trojnar J., Johansson B., Vilhardt H., Åkerlund M.: J. Endocrinol. 111, 125 (1986).
36. Krejčí I.: Bulletin České společnosti pro biochemii a molekulární biologii 30, 67 (2002).
37. Craig L. C.: J. Biol. Chem. 155, 519 (1944).
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2023 Issue 2
Most read in this issue
- Anti-Müllerian hormone – clinical use and future possibilities
- Adnexal torsion in childhood and adolescence
- Specifics of infertility treatment in women with premature ovarian failure
- Severe hepatic rupture in HELLP syndrome